Sirius Neosight has secured €4.4 million in funding to advance its therapeutic prediction platform in oncology, with investments from GO CAPITAL and DEMETER.
Target Information
Sirius Neosight is a biotechnology company specializing in the isolation of Circulating Tumor Cells (CTCs) and the development of functional tests to predict therapeutic responses in oncology. Recently, the company raised €4.4 million in funding to further develop its innovative therapeutic prediction platform.
The funding round was led by GO CAPITAL's seed fund GOCA3 and DEMETER through the Métropolitan Industrial Seed Fund (FAIM) in Lyon/Saint-Etienne. This capital will empower Sirius Neosight to enhance its technological capabilities and expand its market reach within the oncology sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The biotechnology industry in France has been experiencing significant growth, driven by increasing investments in research and development. The landscape is cha
Similar Deals
Kurma Partners, WE Life Sciences, Bpifrance, Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est, Sambrinvest → Elkedonia
2025
GO Capital and Critical Path Ventures → Alkion BioInnovations
2025
Kurma Partners, WE Life Sciences, French Tech Seed fund → Elkedonia
2025
GO CAPITAL, DEMETER
invested in
Sirius Neosight
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $4M